liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Knutsen Holmqvist, Annica
Alternative names
Publications (10 of 14) Show all publications
Andersson, E., Albertsson, M. & Holmqvist, A. (2017). GRACE: Geriatric patients tReated with Avastin in CRC multiple linEs. Clinical Practice, 14(3), 175-182
Open this publication in new window or tab >>GRACE: Geriatric patients tReated with Avastin in CRC multiple linEs
2017 (English)In: Clinical Practice, ISSN 2044-9038, E-ISSN 2044-9046, Vol. 14, no 3, p. 175-182Article in journal (Refereed) Published
Abstract [en]

Continuous treatment with bevacizumab in elderly patients with mCRC: A phase IV prospective, open-label, single-arm trial to evaluate outcomes and safety with continuous bevacizumab treatment in combination with chemotherapy over disease progression.

Place, publisher, year, edition, pages
Future Medicine, 2017
Keywords
Bevacizumab; Capecitabine; Colon cancer; Elderly patients; Rectal cancer
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:liu:diva-147026 (URN)10.4172/clinical-practice.1000111 (DOI)2-s2.0-85029046902 (Scopus ID)
Available from: 2018-04-09 Created: 2018-04-09 Last updated: 2018-04-09
Vernmark, K., Albertsson, M., Björnsson, B., Gasslander, T., Sandström, P., Sun, X.-F. & Holmqvist, A. (2015). From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report. BMC Cancer, 15(884)
Open this publication in new window or tab >>From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report
Show others...
2015 (English)In: BMC Cancer, ISSN 1471-2407, E-ISSN 1471-2407, Vol. 15, no 884Article in journal (Refereed) Published
Abstract [en]

Background: Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is associated with poorer response to chemotherapy and chemoradiotherapy. Case presentation: A 27-year-old Swedish woman presented with stomach pain and weight loss, and was diagnosed with locally advanced MAC in the transverse colon as well as 3 liver metastases. Neoadjuvant treatment with fluorouracil, folinic acid and oxaliplatin (FLOX) failed due to several infections, pulmonary embolism and deteriorated performance status. The patient was therefore considered palliative. Palliative treatment with metronomic capecitabine 500 mg x 2 daily and bevacizumab every other week were initiated. After 4 months of treatment the tumors had regressed and the patient was able to undergo radical surgery, thereby changing the treatment intention from palliative to curative. No adjuvant chemotherapy was given. There were no signs of recurrence 9 months later. Conclusions: The role of the combination of metronomic capecitabine and bevacizumab in patients with MAC merits further investigation.

Place, publisher, year, edition, pages
BIOMED CENTRAL LTD, 2015
Keywords
Mucinous adenocarcinoma; Bevaczumab; Metronomic capecitabine
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-123523 (URN)10.1186/s12885-015-1908-3 (DOI)000365272200003 ()26555668 (PubMedID)
Note

Funding Agencies|foundation of Oncological Clinical Research in Linkoping

Available from: 2015-12-22 Created: 2015-12-21 Last updated: 2017-12-01
Wang, M.-J., Ping, J., Li, Y., Holmqvist, A., Adell, G., Arbman, G., . . . Sun, X.-F. (2015). Prognostic Significance and Molecular Features of Colorectal Mucinous Adenocarcinomas: A Strobe-Compliant Study. Medicine (Baltimore, Md.), 94(51), e2350
Open this publication in new window or tab >>Prognostic Significance and Molecular Features of Colorectal Mucinous Adenocarcinomas: A Strobe-Compliant Study
Show others...
2015 (English)In: Medicine (Baltimore, Md.), ISSN 0025-7974, E-ISSN 1536-5964, Vol. 94, no 51, p. e2350-Article in journal (Refereed) Published
Abstract [en]

Mucinous adenocarcinoma (MC) is a special histology subtype of colorectal adenocarcinoma. The survival of MC is controversial and the prognostic biomarkers of MC remain unclear. To analyze prognostic significance and molecular features of colorectal MC. This study included 755,682 and 1001 colorectal cancer (CRC) patients from Surveillance, Epidemiology, and End Results program (SEER, 1973 2011), and Linkoping Cancer (LC, 1972-2009) databases. We investigated independently the clinicopathological characteristics, survival, and variety of molecular features from these 2 databases. MC was found in 9.3% and 9.8% patients in SEER and LC, respectively. MC was more frequently localized in the right colon compared with nonmucinous adenocarcinoma (NMC) in both SEER (57.7% vs 37.2%, P < 0.001) and LC (46.9% vs 27.7%, P < 0.001). Colorectal MC patients had significantly worse cancer-specific survival (CSS) than NMC patients (SEER, P < 0.001; LC, P = 0.026), prominently in stage III (SEER, P < 0.001; P=0.023). The multivariate survival analysis showed that MC was independently related to poor prognosis in rectal cancer patients (SEER, hazard ratios [HR], 1.076; 95% confidence intervals [CI], 1.057-1.096; P < 0.001). In LC, the integrated analysis of genetic and epigenetic features showed that that strong expression of PINCH (HR, 3.954; 95% CI, 1.493-10.47; P = 0.013) and weak expression of RAD50 (HR 0.348, 95% CT, 0.106-1.192; P=0.026) were significantly associated with poor CSS of colorectal MC patients. In conclusion, the colorectal MC patients had significantly worse CSS than NMC patients, prominently in stage III. MC was an independent prognostic factor associated with worse survival in rectal cancer patients. The PINCH and RAD50 were prognostic biomarkers for colorectal MC patients.

Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS, 2015
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-125839 (URN)10.1097/MD.0000000000002350 (DOI)000369856200034 ()26705231 (PubMedID)
Note

Funding Agencies|National Scientific Foundation of China [81401949, 81300359]; Swedish Cancer Foundation; Swedish Research Council; Health Research Council in the South-East of Sweden

Available from: 2016-03-08 Created: 2016-03-04 Last updated: 2018-03-20
Jung, M., Holmqvist, A., Sun, X.-F. & Albertsson, M. (2014). A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach. Medical Oncology, 31(3), 839
Open this publication in new window or tab >>A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach
2014 (English)In: Medical Oncology, ISSN 1357-0560, E-ISSN 1559-131X, Vol. 31, no 3, p. 839-Article in journal (Refereed) Published
Abstract [en]

Metastasized rectal cancer has long been considered incurable. During recent years, the treatment of rectal cancer patients has been improved, and nowadays, a subgroup of patients might even be cured. The aim of this study was to investigate the optimal timing of treatment in a multimodal therapy schedule in order to see whether the addition of bevacizumab (Avastin) to conventional chemotherapy was effective. The study included 39 patients with metastatic rectal cancer between 2009 and 2011, and three were excluded due to the lack of metastases or lack of follow-up information. The remaining 36 patients were divided into groups by treatment intention. The group with curative intention received mainly oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) with or without bevacizumab (Avastin) for 2 months followed by preoperative radiotherapy (RT) and surgery. Palliative patients had very different treatments depending on their needs of palliation. The median survival time for patients with curative intention was 31 months and for the palliative patients 12 months. Four of the patients (11%) with curative intention were considered cured at the end of follow-up. The response to chemotherapy after 2-month treatment is a good prognostic sign for which patients can be cured. Long-lasting palliation can be obtained with this treatment schedule. The main side effects were gastrointestinal events, including bowel perforation, neuropathy, thrombo-embolic disease and reduced general condition. All side effects are known, and the treatment is considered tolerable. We conclude that a good treatment schedule would be oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) with or without bevacizumab (Avastin) for 2 months, followed by preoperative RT and surgery.

Place, publisher, year, edition, pages
Springer, 2014
Keywords
Rectal cancer, Metastasis, Bevacizumab, Chemotherapy
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-106890 (URN)10.1007/s12032-014-0839-1 (DOI)000337728700005 ()24477647 (PubMedID)
Available from: 2014-05-23 Created: 2014-05-23 Last updated: 2017-12-05Bibliographically approved
Miger, J., Holmqvist, A., Sun, X.-F. & Albertsson, M. (2014). Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Medical Oncology, 31(3), 870
Open this publication in new window or tab >>Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
2014 (English)In: Medical Oncology, ISSN 1357-0560, E-ISSN 1559-131X, Vol. 31, no 3, p. 870-Article in journal (Refereed) Published
Abstract [en]

The prodrug capecitabine (Xeloda) has been an important drug for treatment for gastrointestinal cancer (GI-cancer). This study explores the efficacy of continuous metronomic Xeloda, as well as tolerability and best response during treatment. Patients (n=35) with stage IV GI-cancer were included in the study and were divided into two groups; upper (n=13) and lower (n=22) GI-cancer. All patients were given continuous metronomic Xeloda (500 mg×2). Best response was measured by radiological and clinical examination including laboratory results. Standard RECIST criteria were used. Median age was 66 (range 29-86). Those patients who received first and second line had the longest duration of treatment. For patients with metastatic gastrointestinal cancer, metronomic capecitabine (Xeloda) may be beneficial both as far as tumor control and quality of life is concerned. In this pilot study, palliation for more than 2 years is observed for 6 of the 35 patients.

Place, publisher, year, edition, pages
Springer, 2014
Keywords
Capecitabine, Gastrointestinal cancer, Metronomic treatment, Response, QoL
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-106891 (URN)10.1007/s12032-014-0870-2 (DOI)000337728700034 ()24510794 (PubMedID)
Available from: 2014-05-23 Created: 2014-05-23 Last updated: 2017-12-05Bibliographically approved
Kotti, A., Holmqvist (Knutsen), A., Albertsson, M. & Sun, X.-F. (2014). SPARCL1 Expression Increases With Preoperative Radiation Therapy and Predicts Better Survival in Rectal Cancer Patients. International Journal of Radiation Oncology, Biology, Physics, 88(5), 1196-1202
Open this publication in new window or tab >>SPARCL1 Expression Increases With Preoperative Radiation Therapy and Predicts Better Survival in Rectal Cancer Patients
2014 (English)In: International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, E-ISSN 1879-355X, Vol. 88, no 5, p. 1196-1202Article in journal (Refereed) Published
Abstract [en]

Purpose

The secreted protein acidic and rich in cysteine-like 1 (SPARCL1) is expressed in various normal tissues and many types of cancers. The function of SPARCL1 and its relationship to a patient's prognosis have been studied, whereas its relationship to radiation therapy (RT) is not known. Our aim was to investigate the expression of SPARCL1 in rectal cancer patients who participated in a clinical trial of preoperative RT.

Methods and Materials

The study included 136 rectal cancer patients who were randomized to undergo preoperative RT and surgery (n=63) or surgery alone (n=73). The expression levels of SPARCL1 in normal mucosa (n=29), primary tumor (n=136), and lymph node metastasis (n=35) were determined by immunohistochemistry.

Results

Tumors with RT had stronger SPARCL1 expression than tumors without RT (P=.003). In the RT group, strong SPARCL1 expression was related to better survival than weak expression in patients with stage III tumors, independent of sex, age, differentiation, and margin status (P=.022; RR = 18.128; 95% confidence interval, 1.512-217.413). No such relationship was found in the non-RT group (P=.224). Further analysis of interactions among SPARCL1 expression, RT, and survival showed statistical significance (P=.024). In patients with metastases who received RT, strong SPARCL1 expression was related to better survival compared to weak expression (P=.041) but not in the non-RT group (P=.569).

Conclusions

SPARCL1 expression increases with RT and is related to better prognosis in rectal cancer patients with RT but not in patients without RT. This result may help us to select the patients best suited for preoperative RT.

Place, publisher, year, edition, pages
Elsevier, 2014
National Category
Cancer and Oncology Basic Medicine
Identifiers
urn:nbn:se:liu:diva-106281 (URN)10.1016/j.ijrobp.2013.12.041 (DOI)000333460200031 ()24661672 (PubMedID)
Available from: 2014-05-06 Created: 2014-05-05 Last updated: 2018-01-11Bibliographically approved
Holmqvist (Knutsen), A., Holmlund, B., Ardsby, M., Pathak, S. & Sun, X.-F. (2013). PINCH expression in relation to radiation response in co-cultured colon cancer cells and in rectal cancer patients. Oncology Reports, 30(5), 2097-2104
Open this publication in new window or tab >>PINCH expression in relation to radiation response in co-cultured colon cancer cells and in rectal cancer patients
Show others...
2013 (English)In: Oncology Reports, ISSN 1021-335X, E-ISSN 1791-2431, Vol. 30, no 5, p. 2097-2104Article in journal (Refereed) Published
Abstract [en]

Particularly interesting new cysteine-histidine rich protein (PINCH), involved in cell spreading, motility and proliferation, has been shown to enhance radioresistance in colon cancer cell lines. The expression of PINCH in relation to radiation was studied in co-cultured colon cancer cells. Furthermore, the clinical significance between PINCH and radiotherapy (RT) was analyzed in rectal cancer patients with or without RT. The relative PINCH expression in colon cancer (KM12C) cells cultured separately and in co-culture was examined by western blotting and real-time PCR, and was analyzed over a period of 8 and 24 h after radiation. PINCH expression was immunohistochemically examined in 137 primary rectal tumors for which 65 cases did not receive RT and 72 cases received RT. PINCH expression tended to decrease from that in the separately cultured KM12C cells without radiation to that in cells with radiation at 8 h (P=0.060); while in the co-cultured cells, no significant difference was found (P=0.446). In patients with RT, strong PINCH expression was related to worse survival, when compared to patients with weak expression, independent of TNM stage, degree of differentiation, age and p53 status (P=0.029, RR 4.03, 95% CI 1.34-12.1). No survival relationship for the patients without RT was observed (P=0.287). A statistical interaction analysis between PINCH, RT and survival showed a trend towards significance (P=0.057). In conclusion, PINCH predicts survival in rectal cancer patients with RT, but not in patients without RT. The expression of PINCH may be regulated by radiation and by environmental factors surrounding the cells.

Place, publisher, year, edition, pages
Spandidos Publications, 2013
Keywords
co-culture, immunohistochemistry, PINCH, prognosis, radiation, rectal cancer
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-99392 (URN)10.3892/or.2013.2673 (DOI)000324540300012 ()
Note

Funding Agencies|Foundation of Oncological Clinical Research in Linkoping||Swedish Cancer Foundation||Swedish Research Council||Health Research Council in Southeast Sweden||

Available from: 2013-10-17 Created: 2013-10-17 Last updated: 2017-12-06Bibliographically approved
Holmqvist Knutsen, A., Gao, J.-F., Holmlund, B., Adell, G., Carstensen, J. & Sun, X.-F. (2012). PINCH is an independent prognostic factor in rectal cancer patients without preoperative radiotherapy: A study in a Swedish rectal cancer trial of preoperative radiotherapy. BMC Cancer, 12(65)
Open this publication in new window or tab >>PINCH is an independent prognostic factor in rectal cancer patients without preoperative radiotherapy: A study in a Swedish rectal cancer trial of preoperative radiotherapy
Show others...
2012 (English)In: BMC Cancer, ISSN 1471-2407, E-ISSN 1471-2407, Vol. 12, no 65Article in journal (Refereed) Published
Abstract [en]

Background and Purpose: The clinical significance between particularly interesting new cysteine-histidine rich protein (PINCH) expression and radiotherapy (RT) in tumours is not known. In this study, the expression of PINCH and its relationship to RT, clinical, pathological and biological factors were studied in rectal cancer patients.

Material and Methods: PINCH expression determined by immunohistochemistry was analysed at the invasive margin and inner tumour area in 137 primary rectal adenocarcinomas (72 cases without RT and 65 cases with RT). PINCH expression in colon fibroblast cell line (CCD-18 Co) was determined by Western blot.

Results: In patients without RT, strong PINCH expression at the invasive margin of primary tumours was related to worse survival, compared to patients with weak expression, independent of TNM stage and differentiation (p = 0.03). No survival relationship in patients with RT was observed (p = 0.64). Comparing the non-RT with RT subgroup, there was no difference in PINCH expression in primary tumours (invasive margin (p = 0.68)/inner tumour area (p = 0.49).

Conclusions: PINCH expression at the invasive margin was an independent prognostic factor in patients without RT. RT does not seem to directly affect the PINCH expression.

 

Place, publisher, year, edition, pages
BioMed Central, 2012
Keywords
PINCH, Radiotherapy, Prognosis, Rectal cancer, Immunohistochemistry
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-66104 (URN)10.1186/1471-2407-12-65 (DOI)000301425700001 ()
Note
funding agencies|Swedish Cancer Foundation||Swedish Research Council||Health Research Council in the South-East of Sweden||Available from: 2011-03-04 Created: 2011-03-03 Last updated: 2017-12-11Bibliographically approved
Holmqvist, A. E. (2010). THE LOCATION OF LYMPHANGIOGENESIS IS AN INDEPENDENT PROGNOSTIC FACTOR IN RECTAL CANCERS WITH OR WITHOUT PREOPERATIVE RADIOTHERAPY in ANNALS OF ONCOLOGY, vol 21, issue , pp 212-212. In: ANNALS OF ONCOLOGY (pp. 212-212). Oxford University Press, 21
Open this publication in new window or tab >>THE LOCATION OF LYMPHANGIOGENESIS IS AN INDEPENDENT PROGNOSTIC FACTOR IN RECTAL CANCERS WITH OR WITHOUT PREOPERATIVE RADIOTHERAPY in ANNALS OF ONCOLOGY, vol 21, issue , pp 212-212
2010 (English)In: ANNALS OF ONCOLOGY, Oxford University Press , 2010, Vol. 21, p. 212-212Conference paper, Published paper (Refereed)
Abstract [en]

n/a

Place, publisher, year, edition, pages
Oxford University Press, 2010
National Category
Engineering and Technology
Identifiers
urn:nbn:se:liu:diva-66329 (URN)000283115900672 ()
Available from: 2011-03-11 Created: 2011-03-11 Last updated: 2011-03-17Bibliographically approved
Gao, J., Knutsen Holmqvist, A., Arbman, G., Carstensen, J., Franlund, B. & Sun, X.-F. (2009). Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. DIGESTIVE AND LIVER DISEASE, 41(2), 116-122
Open this publication in new window or tab >>Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer
Show others...
2009 (English)In: DIGESTIVE AND LIVER DISEASE, ISSN 1590-8658, Vol. 41, no 2, p. 116-122Article in journal (Refereed) Published
Abstract [en]

Purpose. The aim of this study was to get a deeper understanding into how adults with cerebral palsy (CP) experience physiotherapy and physical activity in a perspective from childhood to adulthood; and how personal and environmental factors influence possibilities for physiotherapy and physical activity. Method. Data was collected through interviews with 22 community-living adults (35-68 years) with CP, from five counties in Sweden. The questions were open-ended and the interviews were taped and transcribed to written language. The material was analysed through qualitative content analysis, a classification process resulting in different themes. Results. The narratives from the 22 informants, based on experiences from childhood to adulthood, resulted in a description of prerequisites for carrying out physiotherapy and physical activity. Five different themes were identified: (i) Being enjoyable, (ii) Giving effects, (iii) Being comprehensible, (iv) Being integrated in daily life, and (v) Supportive healthcare with competent professionals. Conclusion. The information from the interviews elucidates the importance of a lifelong support from healthcare professionals. Physiotherapists with attentiveness to different life situations in combination with good understanding and knowledge in CP could facilitate continuous physical activity in people growing up and ageing with CP.

Keywords
Angiogenesis, Colorectal cancer, Lymphangiogenesis
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-16973 (URN)10.1016/j.dld.2008.07.315 (DOI)
Note
Original Publication:Jingfang Gao, Annica Knutsen, G Arbman, John Carstensen, B Franlund and Xiao-Feng Sun, Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer, 2009, DIGESTIVE AND LIVER DISEASE, (41), 2, 116-122.http://dx.doi.org/10.1016/j.dld.2008.07.315Copyright: Elsevier Science B.V., Amsterdamhttp://www.elsevier.com/Available from: 2009-03-24 Created: 2009-02-27 Last updated: 2011-03-04Bibliographically approved
Organisations

Search in DiVA

Show all publications